170730-06-0

Basic information

• Product Name: 7-Acetyl-2,3-dihydrobenzofuran
• Synonyms: 7-Acetyl-2,3-dihydrobenzofuran;Ethanone, 1-(2,3-dihydro-7-benzofuranyl)- (9CI);1-(2,3-dihydrobenzofuran-7-yl)ethanone;Ethanone, 1-(2,3-dihydro-7-benzofuranyl);1-(2,3-Dihydro-7-benzofuranyl)ethanone;1-(2,3-Dihydro-7-benzofuranyl)
• CAS NO: 170730-06-0
• Molecular Formula: C₁₀H₁₀O₂
• Molecular Weight: 162.19
• Product Categories: ACETYLGROUP
• Mol File: 170730-06-0.mol

Chemical Properties

• Boiling Point: 294.989 °C at 760 mmHg
• Flash Point: 139.685 °C
• Appearance: /
• Density: 1.149 g/cm³
• Vapor Pressure: 0.002mmHg at 25°C
• Refractive Index: 1.557
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: 7-Acetyl-2,3-dihydrobenzofuran(CAS DataBase Reference)
• NIST Chemistry Reference: 7-Acetyl-2,3-dihydrobenzofuran(170730-06-0)
• EPA Substance Registry System: 7-Acetyl-2,3-dihydrobenzofuran(170730-06-0)

Safety Data

• Hazardous Substances Data: 170730-06-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
7-Acetyl-2,3-dihydrobenzofuran is used as an impurity in the synthesis of Darifenacin for the treatment of urinary incontinence. Darifenacin works by blocking the M3 muscarinic acetylcholine receptor, which helps to reduce the frequency and urgency of urination.
In the synthesis process, the presence of 7-Acetyl-2,3-dihydrobenzofuran as an impurity may affect the purity and efficacy of the final product, Darifenacin. Therefore, it is essential to monitor and control the levels of this impurity during the manufacturing process to ensure the safety and effectiveness of the medication.

InChI:InChI=1/C10H10O2/c1-7(11)9-4-2-3-8-5-6-12-10(8)9/h2-4H,5-6H2,1H3

Upstream product

• 35700-40-4 2,3-dihydrobenzofuran-7-carboxylic acid 
• 917-54-4 methyllithium 
• 1037763-65-7 N-methoxy-N-methyl-2,3-dihydrobenzofuran-7-carboxamide 
• 75-16-1 methylmagnesium bromide 
• 123266-63-7 2,3-Dihydro-7-benzofurancarboxylic acid chloride 

Relevant articles and documents

Vascular endothelial growth factor receptor inhibitor and preparation method and application thereof

The invention provides a vascular endothelial growth factor receptor inhibitor and a preparation method and application thereof, and relates to a quinoline or quinazoline derivative with a structure as shown in a formula (I), a pharmaceutical composition containing a compound as shown in the formula (I) and application of the compound in preparation of drugs for preventing or treating angiogenesis-related diseases, in particular to prevention or treatment of tumors related to protein tyrosine kinase. Each substituent in the formula (I) is the same as the definition in the specification.

Quinoline or quinazoline derivatives, its preparation process and its use in medicine

The invention relates to a quinoline or quinazoline derivative, its preparation method and an application in medicines, specifically to new quinoline or quinazoline derivative as shown in a general formula (I) and its medicinal salt or a pharmaceutical composition containing the derivative and a preparation method thereof. The invention further relates to an application of the quinoline or quinazoline derivative and its medicinal salt or the pharmaceutical composition containing the derivative in the preparation of a therapeutic agent, especially a protein kinase inhibitor. Each substituent group in the general formula (I) has the same definition as in the specification.

The selective 5-HT(1B) receptor inverse agonist 1-methyl-5-[[2'-methyl- 4'(5-methyl-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]carbonyl]-2,3,6,7- tetrahydrospiro[furo[2,3-f]indole-3,4'-piperidine] (SB-224289) potently blocks terminal 5-HT autoreceptor function bo

5-HT1 receptors are members of the G-protein-coupled receptor superfamily and are negatively linked to adenylyl cyclase activity. The human 5-HT(1B) and 5-HT(1D) receptors (previously known as 5-HT(1Dβ) and 5- HT(1Dα), respectively), although e